(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products...
Stats | |
---|---|
今日成交量 | 17 518.00 |
平均成交量 | 14 295.00 |
市值 | 42.11M |
EPS | £0 ( 2024-04-21 ) |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -4.44 |
ATR14 | £0 (0.00%) |
Arecor Therapeutics plc 财务报表
Annual | 2022 |
营收: | £2.40M |
毛利润: | £2.40M (100.00 %) |
EPS: | £-0.320 |
FY | 2022 |
营收: | £2.40M |
毛利润: | £2.40M (100.00 %) |
EPS: | £-0.320 |
FY | 2021 |
营收: | £1.16M |
毛利润: | £1.16M (100.00 %) |
EPS: | £-0.270 |
FY | 2020 |
营收: | £1.70M |
毛利润: | £1.70M (100.00 %) |
EPS: | £-0.0994 |
Financial Reports:
No articles found.
Arecor Therapeutics plc
Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。